Citi Sticks to Their Sell Rating for IndusInd Bank Ltd. (INDUSINDBK)
Citi analyst Kunal Shah CFA maintained a Sell rating on IndusInd Bank Ltd. (INDUSINDBK – Research Report) yesterday and set a price target of INR765.00. The company's shares closed yesterday at INR857.70.
Confident Investing Starts Here:
Shah CFA covers the Financial sector, focusing on stocks such as Axis Bank Limited, AU Small Finance Bank Limited, and Bank of Baroda. According to TipRanks, Shah CFA has an average return of 7.6% and a 74.07% success rate on recommended stocks.
In addition to Citi, IndusInd Bank Ltd. also received a Sell from Morgan Stanley's Sumeet Kariwala in a report issued on June 16. However, on June 18, Nomura upgraded IndusInd Bank Ltd. (NSE: INDUSINDBK) to a Buy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Citi Expresses Optimism for Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now. On June 25, Citi reported that 'compelling' data shows that Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NVO) have turned obesity into a treatable disease from a lifestyle-based condition. The firm models more than $40 billion in obesity sales by 2030, well above the consensus estimates of $25 billion. Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a 'dynamic' consumer-centric market is possible, and LillyDirect by Eli Lilly and Company (NYSE:LLY) is well-positioned to connect high consumer visibility for orforglipron with global access. In a research note, Citi further stated that it estimated penetration rates via income-based tiers for pricing and out-of-pocket costs in low- and mid-body mass index patients. The results place Eli Lilly and Company's (NYSE:LLY) consumer platform opportunity at $15B, which is not assumed in the firm's model. It thus believes that Eli Lilly and Company's (NYSE:LLY) is in a position to expedite access outside the US, employing a centralized out-of-pocket payment model instead of the traditional country-by-country launch. It contended that an 'income-based tiered pricing of orforglipron via LillyDirect could unlock unprecedented volume, all the while allowing it to maintain overall pricing power.' Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies. Investors are bullish on Eli Lilly and Company (NYSE:LLY) due to its in-demand GLP-1 drugs, used to treat diabetes and obesity, which are still in their early growth stages, and the company's strong financials. While we acknowledge the potential of LKQ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Business Upturn
12 hours ago
- Business Upturn
How to read a company's balance sheet: Simple guide for retail investors in India
If you've ever wanted to understand how strong a company is before investing, learning to read a balance sheet is a great place to start. For Indian retail investors, it's one of the most important tools to judge a company's financial health. In this article, let's break down the key sections of a company's balance sheet in simple, easy-to-follow terms—using examples from Indian companies listed on NSE and BSE. What is a balance sheet? A balance sheet is a financial statement that shows what a company owns (assets), what it owes (liabilities), and what's left for shareholders (equity) on a specific date. Formula: Assets = Liabilities + Shareholder's Equity This formula always stays in balance. That's why it's called a balance sheet. 3 key parts of a balance sheet (with Indian examples) Assets (What the company owns) This includes everything the company controls that has value. Current Assets: Short-term assets like cash, bank balances, inventory, and trade receivables (Example: Dabur's inventory and cash reserves) Non-Current Assets: Long-term assets like land, buildings, factories, machinery, or investments (Example: Tata Steel's plants and machinery) Liabilities (What the company owes) These are the company's financial obligations. Current Liabilities: Payments due within a year (Example: Creditors, short-term borrowings – think of Reliance Retail's trade payables) Non-Current Liabilities: Long-term loans or debt (Example: Hindalco's long-term debt from banks) Shareholder's Equity (What belongs to shareholders) This is the net worth of the company. Share Capital: The money raised from shareholders (Example: Infosys' equity capital) Reserves and Surplus: Retained earnings and other reserves (Example: Asian Paints' general reserves and profits over the years) Key ratios you can derive from the balance sheet Debt-to-Equity Ratio: Measures financial risk. Example: Debt-heavy companies like Vodafone Idea vs debt-free companies like Hindustan Unilever. Current Ratio: Shows short-term liquidity (Current Assets / Current Liabilities). Return on Equity (ROE): Shows how efficiently the company is using shareholder's money. Why should Indian investors check the balance sheet? To avoid companies with excessive debt To spot liquidity risks To identify growth in retained earnings over years To compare companies within the same sector Final takeaway For any Indian investor, glancing at the balance sheet before investing is like checking the health report before buying a used car. You don't need to be a CA to read it—just knowing the basics can help you avoid big mistakes. Next time you research a stock, open the company's annual report, go to the balance sheet section, and start reading with this article as your cheat sheet! Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Insider
15 hours ago
- Business Insider
Exane BNP Paribas Remains a Buy on Tata Motors Limited (TATAMOTORS)
In a report released yesterday, Kumar Rakesh from Exane BNP Paribas maintained a Buy rating on Tata Motors Limited (TATAMOTORS – Research Report), with a price target of INR830.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Rakesh covers the Technology sector, focusing on stocks such as HCL Technologies Limited, Infosys Limited, and LTIMindtree Limited. According to TipRanks, Rakesh has an average return of 0.2% and a 41.67% success rate on recommended stocks. In addition to Exane BNP Paribas, Tata Motors Limited also received a Buy from Macquarie's Ashish Jain CFA in a report issued on June 20. However, on June 17, UBS maintained a Sell rating on Tata Motors Limited (NSE: TATAMOTORS).
